Clinical tumor lysis syndrome occurred in 3 of 56 patients ... those with chromosome 17p deletions (deletion 17p CLL), and those with unmutated IGHV. Complete remissions occurred in 20% of the ...

Response to imatinib mesylate in patients with the FIP1L1-PDGFR-alpha positive hypereosinophilic syndrome: Update of a multicenter prospective study and guidelines for eosinophilia diagnosis ...

In addition, larger 5q deletions are associated with either del(17p) or UPD17p ... myelodysplastic syndrome; MPN, myeloproliferative neoplasms. The 5q deletion cohort included men (52%) and women (48% ...

- Venetoclax monotherapy response rates, including Complete Remissions, reported in Phase 2 study of relapsed/refractory chronic lymphocytic leukemia patients with 17p deletion - Study of ...

That mutation, the 17p deletion, makes the disease particularly ... up" dosing on venetoclax to reduce the risk of tumor lysis syndrome, a serious side effect.

The study involved 652 patients, demonstrating zanubrutinib's benefits, especially in high-risk subgroups with 17p deletion, over a median follow-up of 42.5 months. Zanubrutinib resulted in fewer ...

A 17p deletion would probably not be viable and ... region would encompass the LIS1 gene (involved in Miller–Dieker syndrome, MDS). The proband did not show MDS symptoms such as seizures or ...

SEQUOIA arm D study results show better outcomes are possible for patients with 17p-deletion CLL, explained Ian Flinn, MD, PhD, director of lymphoma research at Sarah Cannon Research Institute.

They had previously had a child with developmental delay and dysmorphic features in whom a paternally inherited 4.2-Mb deletion on chromosome 12 between bands 12p11.22 and 12p12.1 had been ...